Zevra Therapeutics (NASDAQ:ZVRA) Coverage Initiated at Cantor Fitzgerald

Cantor Fitzgerald started coverage on shares of Zevra Therapeutics (NASDAQ:ZVRA - Free Report) in a research report sent to investors on Wednesday morning. The brokerage issued an overweight rating and a $25.00 target price on the stock.

ZVRA has been the subject of a number of other reports. Guggenheim initiated coverage on Zevra Therapeutics in a research report on Monday, October 7th. They set a "buy" rating and a $20.00 target price for the company. Canaccord Genuity Group dropped their price objective on shares of Zevra Therapeutics from $25.00 to $23.00 and set a "buy" rating for the company in a research note on Thursday, November 14th. Roth Mkm upped their target price on shares of Zevra Therapeutics from $19.00 to $21.00 and gave the company a "buy" rating in a research report on Tuesday, September 24th. Maxim Group lifted their price target on Zevra Therapeutics from $18.00 to $25.00 and gave the stock a "buy" rating in a research report on Tuesday, September 24th. Finally, HC Wainwright restated a "buy" rating and set a $20.00 price objective on shares of Zevra Therapeutics in a research report on Wednesday, November 20th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $21.57.

Zevra Therapeutics Price Performance

NASDAQ ZVRA traded up $0.29 on Wednesday, reaching $8.53. The company had a trading volume of 426,495 shares, compared to its average volume of 454,739. The stock has a market capitalization of $455.30 million, a PE ratio of -4.33 and a beta of 2.01. Zevra Therapeutics has a 12 month low of $4.20 and a 12 month high of $9.76. The company has a quick ratio of 2.88, a current ratio of 2.88 and a debt-to-equity ratio of 0.84. The firm's 50 day moving average price is $8.78 and its 200 day moving average price is $7.58.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last issued its earnings results on Tuesday, November 12th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.25). Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. The firm had revenue of $3.70 million during the quarter, compared to the consensus estimate of $5.04 million. During the same period last year, the firm posted ($0.40) earnings per share. As a group, equities analysts predict that Zevra Therapeutics will post -1.96 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of ZVRA. International Assets Investment Management LLC raised its holdings in shares of Zevra Therapeutics by 594.0% in the third quarter. International Assets Investment Management LLC now owns 6,940 shares of the company's stock worth $48,000 after buying an additional 5,940 shares during the period. The Manufacturers Life Insurance Company increased its stake in Zevra Therapeutics by 15.2% in the second quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company's stock worth $91,000 after purchasing an additional 2,452 shares during the period. Hunter Associates Investment Management LLC bought a new stake in shares of Zevra Therapeutics during the third quarter worth $92,000. XTX Topco Ltd purchased a new stake in shares of Zevra Therapeutics during the third quarter valued at $94,000. Finally, Intech Investment Management LLC bought a new position in shares of Zevra Therapeutics in the third quarter worth about $95,000. Hedge funds and other institutional investors own 35.03% of the company's stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.